Company Entera Bio Ltd.

Equities

ENTX

IL0011429839

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 12:32:08 2024-04-19 pm EDT			5-day change	1st Jan Change
1.965 ^USD	-12.28%		-33.53%	+230.12%

Apr. 08	Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research	CI
Mar. 26	Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months	CI

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Number of employees: 18

Managers	Title	Age	Since
Miranda Toledano CEO	Chief Executive Officer	47	18-09-26
Dana Yaacov Garbeli DFI	Director of Finance/CFO	40	19-05-31
Anke Hoppe CTO	Chief Tech/Sci/R&D Officer	-	17-12-31
Gregory Burshtein CTO	Chief Tech/Sci/R&D Officer	-	12-08-31
Arthur Santora CTO	Chief Tech/Sci/R&D Officer	73	18-09-20
Hillel Galitzer COO	Chief Operating Officer	45	12-06-30
Roger Garceau BRD	Director/Board Member	70	16-02-29
Irena Ben-Yakar AUD	Comptroller/Controller/Auditor	-	18-12-31

Members of the board	Title	Age	Since
Gerald Lieberman CHM	Chairman	77	13-12-31
Roger Garceau BRD	Director/Board Member	70	16-02-29
Gerald Ostrov BRD	Director/Board Member	73	19-01-09
Miranda Toledano CEO	Chief Executive Officer	47	18-09-26
Yonatan Malca BRD	Director/Board Member	57	10-12-31
Ron Abraham Mayron BRD	Director/Board Member	59	21-04-19
Sean Ellis BRD	Director/Board Member	49	19-03-31
Haya Taitel BRD	Director/Board Member	61	23-06-06

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	35,481,341	28,421,286 ( 80.10 %)	0	80.10 %

Name	Equities	%	Valuation
Knoll Capital Management LP 10.94 %	3,881,879	10.94 %	6 M $
DNA GROUP (T.R.) LTD 10.61 %	3,762,960	10.61 %	6 M $
Centillion Fund, Inc. 6.756 %	2,396,953	6.756 %	4 M $
Arthur Santora 0.8390 %	297,671	0.8390 %	497 111 $
Gerald Lieberman 0.7096 %	251,761	0.7096 %	420 441 $
Miranda Toledano 0.3121 %	110,752	0.3121 %	184 956 $
Sean Ellis 0.2878 %	102,100	0.2878 %	170 507 $
Two Sigma Securities LLC 0.1957 %	69,441	0.1957 %	115 966 $
Renaissance Technologies LLC 0.1618 %	57,400	0.1618 %	95 858 $
Dana Yaacov Garbeli 0.1595 %	56,580	0.1595 %	94 489 $

Entera Bio Ltd.

Kiryat Hadassah Minrav Building

9112002, Jerusalem

+972 2 532 7151

http://www.enterabio.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.24 USD

Average target price

10 USD

Spread / Average Target

+346.43%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ENTERA BIO LTD.	+230.12%	79.48M
VERTEX PHARMACEUTICALS INCORPORATED	-3.06%	102B
REGENERON PHARMACEUTICALS, INC.	+1.72%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.80%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.24%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+18.97%	10.94B

Bio Therapeutic Drugs